Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review

BACKGROUND: The integrase strand transfer inhibitor dolutegravir (DTG) is being introduced into low- and middle-income countries (LMICs) as an alternative to first-line treatment with non-nucleoside reverse transcriptase inhibitors. However, DTG is not yet widely recommended for use in pregnant wome...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Andrew, Clayden, Polly, Thorne, Claire, Christie, Rachel, Zash, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mediscript Ltd 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892677/
https://www.ncbi.nlm.nih.gov/pubmed/29682297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892677/
https://www.ncbi.nlm.nih.gov/pubmed/29682297

Ejemplares similares